Initial Study on COMT and DRD2 Gene Polymorphisms as Well as the Influence of Temperament and Character Trait on the Severity of Alcohol Craving in Alcohol-Dependent Patients

Common and uncommon mouse models of growth hormone deficiency

Mouse models of growth hormone deficiency (GHD) have provided important tools for uncovering the various actions of GH. Nearly 100 years of research using these mouse lines has greatly enhanced our knowledge of the GH/IGF-1 axis. Some of the shared phenotypes of the five "common" mouse models of GHD include reduced body size, delayed sexual maturation, decreased fertility, reduced muscle mass, increased adiposity, and enhanced insulin sensitivity. Since these common mouse lines outlive their normal-sized littermates - and have protection from age-associated disease - they have become important fixtures in the aging field. On the other hand, the twelve "uncommon" mouse models of GHD described herein have tremendously divergent health outcomes ranging from beneficial aging phenotypes (similar to those described for the common models) to extremely detrimental features (such as improper development of the CNS, numerous sensory organ defects, and embryonic lethality). Moreover, advancements in next generation sequencing technologies have led to the identification of an expanding array of genes that are recognized as causative agents to numerous rare syndromes with concomitant GHD. Accordingly, this review provides researchers with a comprehensive up-to-date collection of the common and uncommon mouse models of GHD that have been used to study various aspects of physiology and metabolism associated with multiple forms of GHD. For each mouse line presented, the closest comparable human syndromes are discussed providing important parallels to the clinic.

Confusion of Alcohol Craving With Food Hunger in Alcohol-Dependent Individuals Entering In-Patient Drug Treatment

AIM

To identify the distinguishing characteristics of alcohol dependent patients who confuse alcohol cravings with pre-meal hunger.

METHODS

Data were collected at interview on sociodemographic status, clinical status and anthropometry in 179 patients (163 men and 16 women) undergoing in-patient treatment for alcohol dependence.

RESULTS

A comparison of the patient subgroups studied showed that patients who did not confuse, and those who did confuse, alcohol craving with pre-meal hunger differed significantly in terms of alcohol craving scale scores (9 vs. 4 points). Patients confusing alcohol cravings with pre-meal hunger were more likely to recognize that experiencing severe pre-meal hunger can cause relapse (67.9 vs. 22.8%) and that not being able to distinguish between the sensations under study also increases the risk of breaking abstinence (75.0% vs. 50.4%). This was independent of severity of dependence and intensity of recent alcohol consumption.

CONCLUSIONS

Alcohol-dependent persons who confuse alcohol craving with pre-meal hunger differ from those who do not confuse these hunger pangs in terms of feeling stronger alcohol craving and more frequent occurrence of symptoms accompanying the feeling of alcohol craving during pre-meal hunger. At the start of treatment for alcohol withdrawal, alcohol-dependent individuals who report confusing alcohol cravings with pre-meal hunger are less confident of maintaining abstinence. This is relevant to treatment. The role of possible confounders (depressive symptoms, cognitive and educational deficiency) could not be elucidated definitively.

COMT rs737865 mediates chemobrain in breast cancer patients with various levels of Ki-67

Previous findings have indicated that catechol-O-methyltransferase (COMT) may be a genetic risk factor for chemobrain. However, the mediation of chemobrain by COMT polymorphisms in breast cancer patients with various levels of Ki-67 remains unknown. The current research assessed the genetic risk across COMT genotypes for chemobrain in breast cancer patients with various levels of Ki-67. Breast cancer patients (65 with Ki-67<14%, 75 with Ki-67>14%) completed cognitive tests before and after adjuvant chemotherapy, and three single-nucleotide polymorphisms (SNPs) of COMT (rs165599, rs4680, rs737865) were genotyped from peripheral blood. Lower cognitive test results in breast cancer patients were displayed in those before chemotherapy. Furthermore, the event-based prospective memory (EBPM) scores of patients in the Ki-67>14% group were worse than those in the patients in the Ki-67<14% group after chemotherapy (z=-7.51, P<0.01), but the time-based prospective memory (TBPM) scores of the two groups were not significantly different. The COMT rs737865 A/G genotype was associated with memory protection (codominant model: adjusted odds ratio (OR)=0.135, 95% CI=0.026-0.706, P=0.018), and A/G genotype carriers exhibited better performance on the EBPM test than the A/A genotype. Levels of Ki-67 were likely to be associated with EBPM decline in breast cancer patients. Taken together, COMT rs737865 polymorphisms are a potential genetic risk factor for chemobrain in breast cancer patients with various levels of Ki-67.